Literature DB >> 36060323

Bilateral Linear Porokeratosis Treated With Topical Cholesterol 2%/Lovastatin 2.

Darlene Diep1, Tyler Janitz1, Kamilah S Kannan2, Alison Crane1, Bineetha Aluri1, Kevin Wright3, William Baker1.   

Abstract

Linear porokeratosis is a cutaneous disorder that typically presents in a unilateral linear formation. While the exact cause of linear porokeratosis is unknown, it is thought to be a downstream effect of disrupted cholesterol synthesis and mevalonate accumulation. Our patient is a 61-year-old male with an unusual case presentation of bilateral linear porokeratosis. He had failed numerous standard therapies. Pathologic examination of a skin biopsy was consistent with bilateral linear porokeratosis. Through a PubMed search, there have been limited reported cases of unilateral linear porokeratosis, but there have not been any reported cases of bilateral linear porokeratosis. There are currently limited therapies with satisfactory outcomes for variants of porokeratosis. While there are some studies on the topical application of cholesterol/lovastatin, limited studies have been performed on the linear form. Our study evaluates the efficacy of compounded topical cholesterol 2%/lovastatin 2% ointment on bilateral linear porokeratosis. The patient demonstrated a significant reduction of porokeratotic lesions on the treated arm compared to the untreated arm. Cholesterol/lovastatin is alternative therapy that can be considered in the treatment of linear porokeratosis and other porokeratosis variants.
Copyright © 2022, Diep et al.

Entities:  

Keywords:  bilateral linear porokeratosis; blashko; cholesterol; lovastatin; mevalonate

Year:  2022        PMID: 36060323      PMCID: PMC9428266          DOI: 10.7759/cureus.27540

Source DB:  PubMed          Journal:  Cureus        ISSN: 2168-8184


  6 in total

1.  Second-Hit, Postzygotic PMVK and MVD Mutations in Linear Porokeratosis.

Authors:  Lihi Atzmony; Habib M Khan; Young H Lim; Amy S Paller; Jonathan L Levinsohn; Kristen E Holland; Fatima Nadeem Mirza; Emily Yin; Christine J Ko; Jonathan S Leventhal; Keith A Choate
Journal:  JAMA Dermatol       Date:  2019-05-01       Impact factor: 10.282

2.  Topical cholesterol/lovastatin for the treatment of porokeratosis: A pathogenesis-directed therapy.

Authors:  Lihi Atzmony; Young H Lim; Claire Hamilton; Jonathan S Leventhal; Annette Wagner; Amy S Paller; Keith A Choate
Journal:  J Am Acad Dermatol       Date:  2019-08-23       Impact factor: 11.527

3.  Linear porokeratosis with multiple squamous cell carcinomas successfully treated by electrochemotherapy.

Authors:  M Sommerlad; A Lock; G Moir; J McGregor; R Bull; R Cerio; C Harwood
Journal:  Br J Dermatol       Date:  2016-08-17       Impact factor: 9.302

4.  Metabolic Induction of Trained Immunity through the Mevalonate Pathway.

Authors:  Siroon Bekkering; Rob J W Arts; Boris Novakovic; Ioannis Kourtzelis; Charlotte D C C van der Heijden; Yang Li; Calin D Popa; Rob Ter Horst; Julia van Tuijl; Romana T Netea-Maier; Frank L van de Veerdonk; Triantafyllos Chavakis; Leo A B Joosten; Jos W M van der Meer; Henk Stunnenberg; Niels P Riksen; Mihai G Netea
Journal:  Cell       Date:  2018-01-11       Impact factor: 41.582

Review 5.  Cornoid lamellation revisited: apropos of porokeratosis with emphasis on unusual clinicopathological variants.

Authors:  Asok Biswas
Journal:  Am J Dermatopathol       Date:  2015-02       Impact factor: 1.533

6.  Linear porokeratosis with bone abnormalities treated with compounded topical 2% cholesterol/2% lovastatin ointment.

Authors:  Elliot Blue; James Abbott; Anneli Bowen; Sarah D Cipriano
Journal:  Pediatr Dermatol       Date:  2020-11-10       Impact factor: 1.588

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.